Ionis Pharmaceuticals

Youtube Subscribe

Open: 38.88 Close: 39.2 Change: 0.32

The unbelievably easy way to evaluate Ionis Pharmaceuticals: Use an AI.

This document will help you to evaluate Ionis Pharmaceuticals without reading an infinite amount of sources. Relying only on stock quotes or prices to make investment decisions is a mistake. Analyzing and observing stock charts, highs and lows and other numerical data does not allow to evaluate the real value of a company. Stock quotes and prices are the result of underlying characteristics of a company and of events and news happening around them. For this reason, investing must be based on information, not numbers. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Ionis Pharmaceuticals are: Ionis, Pharmaceuticals, company, share, IONS, year, quarter, …

Concept Map

Semantic Network

Stock Summary

SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin am.

Today's Summary

Needham & Company LLC reiterated their “buy” rating and set a price target of $60.00. The biotech company specializes in discovering and developing RNA-targeted therapeutics.

Today's News

Ionis Pharmaceuticals (NASDAQ: IONS) plunged 14% in yesterdays trade to its five year low levels of $30. The biotech company specializes in discovering and developing RNA-targeted therapeutics. Needham & Company LLC reiterated their “buy” rating and set a price target of $60.00. Ionis Pharmaceuticals, Inc. to hold first quarter 2023 financial results webcast. The leading companies are working in the Familial Chylomicronemia Syndrome market. Ionis Pharmaceuticals (IONS) reported earnings of -$0.60 per share, beating the Zacks Consensus Estimate of $-0.94 per share. Free cash flow was $313 million versus negative $112 million in the prior year. Ionis Pharmaceuticals (NASDAQ:IONS) now covered by stocknews.com - defense world.com. CEO Brett P. Quilter Plc acquired a new stake in shares of Ionis pharmaceuticals during the 1st quarter worth approximately $360,459,000. The company last issued its quarterly earnings results on Wednesday, August 9th.

Stock Profile

"Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops Cimdelirsen to inhibit the production of growth hormone receptor; IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. Ionis Pharmaceuticals, Inc. was incorporated in 1989 and is based in Carlsbad, California."

Keywords

The game is changing. There is a new strategy to evaluate Ionis Pharmaceuticals fundamental value, possible risks and most salient advantages. Investors have traditionally relied in reading large amounts of text to evaluate the fundamental value of a stock or company. However, the development of Artificial Intelligence (AI) tools is modifying the way investments are evaluated in markets. Today, machine learning, natural language processing and bigdata allow making this process automatic, reducing large amounts of text to the elements that have a higher activation in a neural network. We programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Ionis Pharmaceuticals are: Ionis, Pharmaceuticals, company, share, IONS, year, quarter, and the most common words in the summary are: pharmaceutical, llc, inc, excipient, ionis, phase, stock, . One of the sentences in the summary was: The biotech company specializes in discovering and developing RNA-targeted therapeutics.. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #pharmaceutical #llc #inc #excipient #ionis #phase #stock.

Read more →

Youtube Subscribe

---